

1 October 2015

The Manager
Companies Announcement Office
Australian Securities Exchange
Electronic Lodgment

Dear Sir/Madam,

**ASX RELEASE – MOU ON PROPOSED COLLABORATION WITH JISENKAI
MEDICAL CORPORATION AIZAWA HOSPITAL ON PROTON THERAPY**

The Board of Directors (the “Board”) of Asian American Medical Group Limited (“AAMG” or “the Company”) wishes to announce that its wholly-owned subsidiary, Asian American Radiation Oncology Pte. Ltd (“AARO”), has on 1 October 2015 entered into a non-binding memorandum of understanding (“MOU”) with Jisenkai Medical Corporation Aizawa Hospital (“Aizawa Hospital”) (collectively, the “Parties” and each, a “Party”).

Aizawa Hospital is a 502-bed private general hospital located in Matsumoto in Nagano Prefecture, Japan. It operates the Aizawa Comprehensive Cancer Center (“ACCC”) which provides complete multidisciplinary cancer treatment services including chemotherapy, radiotherapy, palliative care, psycho-oncology and proton beam therapy (“Proton Therapy”). Its Proton Therapy facility is equipped with the world’s first vertical compact single rotating gantry proton therapy system.

Under the terms of the MOU, both Parties will identify suitable areas of collaboration, such as proton therapy services, which include the potential establishment of Proton Therapy Clinic(s) to be operated by AARO.

Both Parties will commit to an exclusive partnership to explore opportunities for the establishment of Proton Therapy services in Singapore, Northeast Asia and South East Asia, leveraging on AARO’s international network and Aizawa Hospital’s well-established reputation of having one of the world’s most modern and best-equipped proton therapy facility.

The collaboration contemplated by the MOU will be effective for two months from 1 October 2015.

For more information, please contact:

DARIO NAZZARI
Company Secretary
Tel: +61 8 8110 0999
Email: dario@uhyhn.com.au

For personal use only

About Asian American Medical Group

Asian American Medical Group (“AAMG”) is based in Singapore and has been listed on the Australian Securities Exchange since September 2009. The Group’s operations include the Asian American Liver Centre Pte Ltd (“AALC”), established in 1994 in Singapore, and Asian American Radiation Oncology Pte Ltd (“AARO”).

The Group entered into a strategic collaboration in October 2012 with the US-based US\$11-billion integrated global health enterprise UPMC. UPMC, ranked No. 12 on the U.S. News & World Report Honor Roll of American’s Best Hospitals, is affiliated with the University of Pittsburgh Schools of the Health Sciences and are pioneers in the field of transplantation. This collaboration has enhanced AAMG’s clinical capabilities through shared protocols, rigorous quality standards and technology and also created a platform for AAMG to expand into other countries in Asia such as Malaysia and Myanmar.

AALC, one of Asia’s foremost liver centres, is led by renowned hepatobiliary expert and liver transplant surgeon, Dato’ Dr. Tan Kai Chah (Dr. KC Tan), who helped start the Liver Transplant Programme at the King’s College Hospital London, UK, and pioneered the highly successful Living Donor Liver Transplantation (LDLT) Programme in Singapore. In 2004, AALC begun conducting surgical procedures at IHEAL Medical Centre, located in Kuala Lumpur, Malaysia.

AARO, established in March 2015, offers radiation oncology clinical, consultancy and management services and is spearheaded by Dr Daniel Tan Yat Harn. Based in Singapore, AARO will drive expansion into the growing radiotherapy and oncology segment in the overseas market, at a time where there is a shortage of modern radiotherapy treatment centres.

For further information, please visit www.aamg.co.

Media enquiries

WeR1 Consultants

Ms Sheryl Sim; sheryl@wer1.net

Ms Rachael De Foe; rachaeldefoe@wer1.net

Tel: +65 6737 4844